Dr. Reddy's Laboratories Limited (NYSE: RDY) was downgraded by analysts at Nomura from a "buy" rating to a "neutral" rating.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio [Yahoo! Finance]
Heparin Market to Grow by USD 3.34 Billion (2024-2028), Driven by Coagulation Disorder Prevalence and AI Impacting Market Trends - Technavio [Yahoo! Finance]
Theranica Advances Migraine Care in 2024 Supported by New Research, an Expanded Indication, a new Chief Medical Officer, and Broader Insurance Coverage [Yahoo! Finance]
Dr. Reddy's Laboratories Limited (NYSE: RDY) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.